Scaling up antiretroviral therapy in developing countries: What are the benefits and challenges?

Postgraduate Medical Journal

Volumn 84, Issue 991, 2008, Pages 225-227

  Boulle, A ^a   Ford, N ^b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b Médicins San Frontières ^*  (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; EDITORIAL; FOLLOW UP; HEALTH CARE ACCESS; HEALTH PROGRAM; HEALTH SERVICE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE ADHERENCE; MONITORING; MORTALITY; RISK BENEFIT ANALYSIS; SURVIVAL; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS RESISTANCE;

EID: 47149110873     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.2007.027748     Document Type: Editorial

References (40)

1. Gilks C, AbouZhar C, Turmen T. HAART in Haiti - evidence needed. Bull World Health Organ 2001;79:1154-5.
2. Harries AD, Nyangulu DS, Hargreaves NJ, et al. Preventing antiretroviral anarchy in sub-Saharan Africa. Lancet 2001;358:410- 4.
3. Marseille E, Hofmann PB, Kahn JG. HIV prevention before HAART in sub-Saharan Africa. Lancet 2002;359:1851-6.
4. Loewenson R, McCoy D. Access to antiretroviral treatment in Africa. BMJ 2004;328:241-2.
5. McCoy D, Chopra M, Loewenson R, et al. Expanding access to antiretroviral therapy in sub-saharan Africa: avoiding the pitfalls and dangers, capitalizing on the opportunities. Am J Public Health 2005;95:18-22.
6. Farmer P, Leandre F, Mukherjee J, et al. Community-based treatment of advanced HIV disease: introducing DOT-HAART (directly observed therapy with highly active antiretroviral therapy). Bull World Health Organ 2001;79:1145-51.
7. Hogan DR, Salomon JA. Prevention and treatment of human immunodeficiency virus/acquired immunodeficiency syndrome in resource-limited settings. Bull World Health Organ 2005;83:135-43.
8. Cleary SM, McIntyre D, Boulle AM. The cost-effectiveness of antiretroviral treatment in Khayelitsha. South Africa - a primary data analysis. Cost Eff Resour Alloc 2006;4:20.
9. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006;367:817- 24.
10. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006;296:782-93.
11. Libamba E, Makombe SD, Harries AD, et al. Malawi's contribution to "3 by 5": achievements and challenges. Bull World Health Organ 2007;85:156-60.
12. Van Cutsem G, Hilderbrand H, Coetzee D, et al. Clinical outcomes and emerging challenges after 5 years of ART in Khayelitsha, South Africa. 14th Conference on Retroviruses and Opportunistic Infections, 2007.
13. Etard JF, Ndiaye I, Thierry-Mieg M, et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 2006;20:1181-9.
14. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004;18:887-95.
15. Lawn SD, Myer L, Hading G, et al. Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis 2006;43:770- 6.
16. Martinson NA, Karstaedt A, Venter WF, et al. Causes of death in hospitalized adults with a premortem diagnosis of tuberculosis: an autopsy study. AIDS 2007;21:2043-50.
17. Yu JK, Chen SC, Wang KY, et al. True outcomes for patients on antiretroviral therapy who are "lost to follow-up" in Malawi. Bull World Health Organ 2007;85:550-4.
18. Egger M, Boulle A, Schechter M, et al. Antiretroviral therapy in resource-poor settings: scaling up inequalities? Int J Epidemiol 2005;34:509-12.
19. Fairall L, Bachmann M, Louwagie G, et al. Effectiveness of antiretroviral treatment in a South African program: cohort study. Ann Intern Med. In press.
20. Marins JR, Jamal LF, Chen SY, et al. Dramatic improvement in survival among adult Brazilian AIDS patients. AIDS 2003;17:1675-82.
21. Teixeira PR, Vitoria MA, Barcarolo J. Antiretroviral treatment in resource-poor settings: the Brazilian experience. AIDS 2004;18(Suppl 3):S5-S7.
22. Laubsher R, Bradshaw D, Bourne D, et al. Rapid surveillance of AIDS mortality in South Africa (437). 3rd South African AIDS Conference, 2007.
23. Braitstein P, Boulle A, Nash D, et al. Gender and the use of potent antiretroviral treatment in resource-constrained settings: Findings from a multi-centre collaboration. J Women's Health. In press.
24. Orrell C, Harling G, Lawn S, et al. Conservation of first line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther 2006., In press.
25. Coetzee D, Boulle A, Hildebrand K, et al. Promoting adherence to antiretroviral therapy: the experience from a primary care setting in Khayelitsha, South Africa. AIDS 2004;18(Suppl 3):S27-S31.
26. Egger M. Outcomes of ART in resource-limited and industrialized countries. 14th Conference on Retroviruses and Opportunistic Infections, 2007.
27. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006;296:679-90.
28. Bussmann H, Novitsky V, Wester W, et al. HIV-1 subtype C drug-resistance background among ARV-naive adults in Botswana. Antivir Chem Chemother 2005;16:103-15.
29. Bessong PO, Mphahlele J, Choge IA, et al. Resistance mutational analysis of HIV type 1 subtype C among rural South African drug-naive patients prior to large-scale availability of antiretrovirals. AIDS Res Hum Retrovir 2006;22:1306-12.
30. Kamya MR, Mayanja-Kizza H, Kambugu A, et al. Predictors of long-term viral failure among Ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr 2007;46:187- 93.
31. Kennedy C, O'Reilly K, Medley A, et al. The impact of HIV treatment on risk behaviour in developing countries: a systematic review. AIDS Care 2007;19:707-20.
32. Berkman A. Confronting global AIDS: prevention and treatment. Am J Public Health 2001;91:1348-9.
33. Médecins Sans Frontières. Help wanted. Confronting the health care worker crisis to expand access to HIV/AIDS treatment: MSF experience in southern Africa. Johannesburg: Médecins Sans Frontières, 2007.
34. Parkhurst JO, Lush L. The political environment of HIV: lessons from a comparison of Uganda and South Africa. Soc Sci Med 2004;59:1913-24.
35. Harries AD, Schouten EJ, Libamba E. Scaling up antiretroviral treatment in resource-poor settings. Lancet 2006;367:1870-2.
36. Boulle A, Orrel C, Kaplan R, et al. Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther 2007;12:753-60.
37. Calmy A, Hirschel B, Cooper DA, et al. Clinical update: adverse effects of antiretroviral therapy. Lancet 2007;370:12-4.
38. Ford N, Wilson D, Costa CG, et al. Sustaining access to antiretroviral therapy in the less-developed world: lessons from Brazil and Thailand. AIDS 2007;21(Suppl 4):S21-S29.
39. Havlir DV, Hammer SM. Patents versus patients? Antiretroviral therapy in India. N Engl J Med 2005;353:749-51.
40. Calmy A, Ford N, Hirschel B, et al. HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis 2007;44:128-34.